Skip to main content
SpringerLink
Log in

Consider endocrine and metabolic effects when selecting an antipsychotic, then monitor and manage accordingly

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia: second edition [online]. Available from URL: http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=Schizophrenia2e_Inactivated_04-16-09 [Accessed 2010 Apr 29]

  2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27(2): 596–601

    Article  Google Scholar 

  3. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64(20): 2291–314

    Article  PubMed  CAS  Google Scholar 

  4. Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry 2007; 68Suppl. 4: 14–8

    PubMed  Google Scholar 

  5. Bhuvaneswar CG, Baldessarini RJ, Harsh VL, et al. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs 2009; 23(12): 1003–21

    Article  PubMed  CAS  Google Scholar 

  6. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004 Aug; 161(8): 1334–49

    Article  PubMed  Google Scholar 

  7. Ma RC, Kong AP, Chan N, et al. Drug-induced endocrine and metabolic disorders. Drug Saf 2007; 30(3): 215–45

    Article  PubMed  CAS  Google Scholar 

  8. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68Suppl. 4: 8–13

    PubMed  Google Scholar 

  9. Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007 Aug; 61(8): 1356–70

    Article  PubMed  CAS  Google Scholar 

  10. Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidaemia. J Clin Psychiatry 2007; 68Suppl. 4: 34–9

    PubMed  Google Scholar 

  11. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353(12): 1209–23

    Article  PubMed  CAS  Google Scholar 

  12. Meulendijks D, Mannesse CK, Jansen PAE, et al. Antipsychotic-induced hyponatraemia: a systematic review of the published evidence. Drug Saf 2010; 33(2): 101–14

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Consider endocrine and metabolic effects when selecting an antipsychotic, then monitor and manage accordingly. Drugs Ther. Perspect 26, 24–26 (2010). https://doi.org/10.2165/11205280-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11205280-000000000-00000

Search

Navigation